Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab (Monjuvi) combined with lenalidomide (Revlimid) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
According to Salles, 50% of patients experienced a drop in white blood cell count and 1/3 of patients required an injection to boost count. Additionally, 1 in 6 patients experienced infection that may led to hospitalization. Most of these infections were common, however some lead to hospitalization. No instances of septic shock were reported.
Anemia occurred in 1/3 of patients. Patients also experienced platelet cell diminishment. One in 6 patients required treatment for these adverse events.
Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL
Published: December 8th 2024 | Updated: December 8th 2024The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL
August 15th 2024During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
